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Conclusion  
- This series supports the safe use of these SBRT schemes, 
with effective biological doses, low toxicity in central 
tumors, low rate of rib fractures and excellent tolerance. 
- Stereotactic radiotherapy is a feasible, safe, and 
effective procedure for the treatment of Stage I non–
small-cell lung cancer or metastases. It promises high 
local control with a reduced overall treatment time. 
- Tumors with high initial SUV had higher rate of local 
relapse. 
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Purpose or Objective  
To assess dosimetric and clinical outcomes for relatively 
large and mobile T2 tumors of lung. 
Material and Methods  
All patients diagnosed with histologically confirmed 
T2N0M0  non-small cell lung cancer (NSCLC) suitable to 
undergo SABR based on multi-disciplinary tumor board, 
underwent respiratory training consisting of DIBH on 
demand for 15-25 seconds at a time. Patients underwent 
2 sets of immobilization and imaging, one in DIBH phase 
and other in free breathing (FB) phase. Respiratory 
monitoring was performed using Varian RPM system and a 
4mm gating threshold window was allowed. Set-up 
verification was performed using KV imaging and gated 
cone beam CT both taken in DIBH/FB depending on the 
type of treatment. All except 4 patients were treated 
with 2-4 arc VMAT using 6MV flattening filter free (FFF) 
photon beams to a dose of 60Gy in 5-8 fractions in DIBH. 
Rest were treated in FB phase. Follow-up imaging was 
performed at 3 months interval till 9 months and then 
yearly thereafter. For each patient, DIBH plans were 
dosimetrically compared to FB plans. 
Results  
A total of 33 patients with median age of 63 years 
diagnosed with T2N0M0 (staged with PET and EBUS) found 
suitable for SABR during the study period. With a median 
follow-up of 30 months, 3 yrs local control was 90% and 
overall survival was 81%. None of the patients had 
significant (>3 grade) early toxicities. 2 patients had 
grade-3 pneumonitis and 3 patients had grade-3 chest 
wall pain due to rib fractures. DIBH resulted in 1.63 times 
higher mean lung volumes (3956cc vs. 2511cc, p=0.002). 
Compared to ITV based contours, PTV volumes were 1.51 
times smaller in DIBH CT compared to FB CT (35.98 cc vs. 
53.68 cc, p=0.002). All the plans accepted for delivery 
met the standard criteria for both target and OAR 
constraints. On an average, V20 was reduced by 30%(17-
39) in DIBH plans compared to FB plans. Time taken to 
deliver each session in DIBH phase with FFF beams was 
longer by an average of 2 minutes due to interruptions 
(maximum 4 interruptions/arc each lasting <15 seconds). 
Daily mean setup errors in cm quantified on CBCT were 
0.1, 0.2 and 0.1 in vertical, longitudinal and lateral 
dimensions respectively and a uniform margin (based on 
Van Herk's formula) of 4mm appears to be safe.  
Conclusion  
SABR is clinically deliverable and results in good clinical 
outcomes in T2 lung tumors. DIBH based SABR is 
dosimetrically superior to FB based SABR and is feasible 
in a great majority of the patients. DIBH-CBCT based 
verification is reproducible and effective in reducing 
setup errors. A margin of 4 mm is safe in DIBH setting 
with 4 mm gating threshold window.  
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Purpose or Objective  
Retrospective evaluation of the outcome of patients 
treated with SABR with curative intent for peripheral 
stage I lung cancer. 
Material and Methods  
In 2007, a SABR protocol was launched for patients with 
stage I NSCLC. Patients with central lesions, multiple 
nodules, metastatic lung lesions or synchronous cancers 
were excluded from this review. A diagnostic PET-CT was 
obtained for all patients.The prescribed dose was 4 
fractions of 12Gy to a total dose of 48Gy for all 
patients.In 2010, the treatment technology evolved for 3 
phases to 10 phases 4D-CT,from type I to type II dose 
calculations,from multiple conformal beams to VMAT, 
from movie portal images or megavoltage scans to 
systematic use of CBCT scan as IGRT method. Local 
control was defined as the absence of progression.All 
suspected local relapses were considered as 
confirmed.Toxicities were graded according to the CTCAE 
v4.0.  
Results  
Between 11/2007 and 06/2016, 300 patients were 
treated according this SABR protocol. 67 patients treated 
for metastases, 44 patients treated for multiple nodules 
and synchronous cancers were excluded, the 189 
remaining patients were treated with SABR for a single 
primary lung lesion. Patients were 46 to 90 years-old, 66% 
were men, 93% were smokers or ex-smokers. Diagnosis 
was histologically confirmed in 41% patients (21% 
adenocarcinoma, 14% SCC, 6% NOS NSCLC), while it was 
based on radio-metabolic criteria including size increase 
in 59% patients. AJCC 7 Stage distribution was:T1a: 59%, 
T1b: 30%, T2: 11%, all patients were N0 and M0. Contra-
indications to surgery were mostly pulmonary, cardiac, 
and/or general; only 4% of the patients refused surgery. 
After 4.1 years of median follow up, the cumulative 
incidence (analyzed in a competing risks framework) of 
local, regional and metastatic relapse are respectively 
12%, 6% and 16%. After one, two and four years, the OS 
(estimated with Kaplan-Meier method) was respectively 
83 %, 65 % and 37% while the RFS was respectively 75%, 
49% and 31%, with a median OS of 37 months. No grade 4 
or 5 toxicities were observed. Grade 1 to 3 toxicities 
were: fatigue (41%), chest wall pain (10%), dyspnea (7%), 
radiation pneumonitis (total: 4%, grade 3: 2%), dermatitis 
(4%), cough (3%), rib fracture (2%), and esophagitis (1%). 
Metastatic control was significantly better for patients 
without a previous cancer history (70% versus 59%, cause 
specific hazard ratio for metastatic relapse 3,04; CI 1,21-
7,66, p = 0.02). We did not detect an impact of tumor 
stage on survival or loco-regional or distant control. The 
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local control improved for the recent period from 81% to 
91 %, raising the hypothesis of favorable impact of new 
technologies (cause specific hazard ratio for local relapse 
0,39, CI 0,15-1,01, p=0,05). 
Conclusion  
Local control and other clinical outcomes after SABR for 
peripheral Stage I lung cancer in this large series of frail 
patients compares to other reports. Further studies are 
needed to confirm the positive effect observed with the 
use of more recent radiation methods. 
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Purpose or Objective  
For patients with early-stage primary lung cancer and/or 
oligometastatic lung tumors of extrapulmonary histology, 
surgery is the accepted primary treatment approach. 
However, for those who are medically inoperable or 
refuse resection, stereotactic body radiation therapy 
(SBRT) is an alternative treatment producing excellent 
local control (LC). Given the results of Trakul et al. 
(IJROBP 2012), showing equivalency of excellent (>90%) 
1-year LC between single-fraction (18-25 Gy) and multi-
fraction (50-60 Gy in 3-5 fractions) regimens, our 
institution has utilized 25 Gy in a single fraction (BED10 
87.5 Gy) for peripheral tumors ≤5 cm. We report clinical 
outcomes and toxicity of <30 Gy single-fraction SBRT. 
Material and Methods  
We conducted a retrospective review of all patients with 
lung metastases treated with single fraction, robotic 
SBRT at our institution from 2011-2016. 101 lung lesions 
from 36 patients were identified with median follow up 
28 months (range, 7-74). For LC, patients were censored 
at last imaging (stable/improved) or time of progression. 
Kaplan-Meier and Cox proportional hazard analyses were 
performed. 
Results  
Median patient KPS was 90 (range, 70-100), with 88% of 
patients considered to be oligometastatic (1-5 lung 
lesions, and ≤1 extra-pulmonary sites treated 
definitively). 50% of patients were medically non-
operable, while 50% refused resection. Primary cancer 
sites included bone/soft tissue sarcoma (27%), colorectal 
(25%), renal (14%), endometrial (13%), head and neck 
(8%), and other (13%). 27% of treated nodules had 
concurrent systemic therapy. Most lesions received 25 Gy 
(84%) or 20 Gy (11%) (range, 15-29). Median number of 
lesions treated per patient was 3 (range, 1-10). Median 
PTV was 4.8 cc (range, 0.5-85.5), all with PTV coverage 
≥95%. LC (±SE) at 1 and 2 yrs, by nodule, was 67±5% and 
49±6%, respectively. LC was diminished as a function of 
lesion size (cm) irrespective of PTV (HR 1.4±0.1, 
p<0.014), with 1 yr LC of 82±5% vs 48±8% for lesions ≤1 
cm vs > 1 cm, respectively, p<0.001.  LC was also 
reduced for adenocarcinoma vs others (HR 3.2±0.3, 
p<0.001). Median time to pulmonary progression (outside 
treated lesions) was 8 months (range, 0.4-52). Median 
time to extrapulmonary progression was 13 months 
(range, 0.4-48). Median OS was 32 months (7-74). AEs 
were rare, with 2 of 36 patients experiencing transient 
grade ≤2 pneumonitis after SBRT. 
Conclusion  
While single-fraction SBRT at <30 Gy was safe, LC per 
nodule was lower for larger lesions. 30 Gy single-fraction 
SBRT for lung metastasis was abandoned in a recent 
Phase 2 study due to decreased LC compared to multi-
fraction regimens (Nuyttens et al. IJROBP 2015). 
Hamamoto et al. (Jap J Clin Oncol 2009) found worse LC 
for metastatic vs primary lung lesions at the same dose. 
Uncertainty in setup and tumor motion management may 
have contributed to diminished LC (Braunstein et al. 
IJROBP 2014). For metastases >1.0 cm and/or 
adenocarcinoma, higher BED10 regimens are strongly 
indicated, although may yield increased toxicity. 
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Purpose or Objective  
Stereotactic Body Radiotherapy (SBRT) has become the 
standard radiation therapy for inoperable stage I non-
small cell lung cancer (NSCLC) patients. We analyse 
retrospectively the results of survival and local control in 
two series of 25 and 48 patients treated with 
conventional radiation therapy (EBRT) and stereotactic 
body radiotherapy respectively at our centre. 
Material and Methods  
From May 2006 to February 2010, 90 patients were 
treated with EBRT (66Gy, 33 fractions) inside a Spanish 
national phase II trial which compared EBRT against EBRT 
combined with erlotinib. At our centre, 25 patients were 
stage I NSCLC (13 had treatment combined with erlotinib, 
52%). All of them had histological proven NSCLC T1-
T2aN0M0. After its introduction in 2011, SBRT became 
the standard treatment for this group of patients. From 
August 2011 to September 2016, 48 patients were treated 
with SBRT (48-60Gy in 3-8 fractions), only 26 with NSCLC 
histological confirmation (55.2%). We compared 
retrospectively both local control and overall survival 
(OS) for these two groups of patients using Kaplan Meier 
from SPSS20. 
Results  
Local control at 1-year in SBRT group was 97.5% versus 
65.4% in the EBRT group and at 3-years 87.8% versus 45%, 
respectively (p < 0.05). The median OS was 31.5 months 
versus 15 months for SBRT and EBRT, respectively, with 
an OS of 81% and 64% for SBRT and EBRT at 1- year 
respectively, and at 3-year 56% and 4% (p<0.05). 
   
